Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
AnaptysBio completed the spin-off of First Tracks Bio, transitioning exclusively to a financial collaboration manager with a target EBIT margin greater than 95%. Jemperli royalties increased 44% year-over-year to $24.7 million on $313 million in partner sales, while the company authorized a $100 million stock repurchase program.
Key figures
- Revenue
- $25.6 million
- Guidance
- Expects >$390 million in annualized Jemperli royalties by 2029; Imsidolimab PDUFA date set for Dec. 12, 2026
- Cash position
- $286.5 million
- Jemperli sales
- $313 million
- Jemperli royalties
- $24.7 million
- Royalty yoy growth
- 44%
- Stock repurchase plan
- $100.0 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.